Find a Trial

Trial Results


207 protocol(s) meet the specified criteria
1381-0009OPEN TO ACCRUAL
1808097542OPEN TO ACCRUAL
Racial Disparities in Curative Therapies for Hepatocellular Carcinoma
1811529718OPEN TO ACCRUAL
Introducing Palliative Care (PC) within the Treatment of End Stage Liver Disease (ESLD): A Cluster Randomized Controlled Trial
20170543OPEN TO ACCRUAL
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100).
2018-0877OPEN TO ACCRUAL
Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)
207497OPEN TO ACCRUAL
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma DREAMM-6
516-003OPEN TO ACCRUAL
A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma
9812-11OPEN TO ACCRUAL
Laboratory Studies of Peripheral Blood and Bone Marrow Cells Isolated from Patients with Clonal Myeloid or Lymphoproliferative Disorders
A021502OPEN TO ACCRUAL
RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR
ARO-021OPEN TO ACCRUAL
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
ASTX727-03OPEN TO ACCRUAL
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
BL007OPEN TO ACCRUAL
A Rollover Study to Follow the Durability of Response for Patients from Study UT001 (Formerly TC-UT-03, Post-marketing Commitment) and Study TC-BC-12
BLCCOPEN TO ACCRUAL
Blue Light Cystoscopy with Cysview (BLC with Cysview) Registry
BMTCTN1702OPEN TO ACCRUAL
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)
BTCRC-AML17-113OPEN TO ACCRUAL
Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
BTCRC-LUN17-127OPEN TO ACCRUAL
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer
C16-168OPEN TO ACCRUAL
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
C16-174OPEN TO ACCRUAL
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CC06-C-0213OPEN TO ACCRUAL
Tissue Procurement Protocol for the Development Therapeutics Clinic, National, Cancer Institution (NCI)
CTO-17-101OPEN TO ACCRUAL
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
CTO-20180144OPEN TO ACCRUAL
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
CTO-20190135OPEN TO ACCRUAL
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
CTO-208887OPEN TO ACCRUAL
A Phase I/II Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM5
CTO-A011801OPEN TO ACCRUAL
THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB
CTO-A031704OPEN TO ACCRUAL
PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]
CTO-ALLOVIR-P-105-202OPEN TO ACCRUAL
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Viralym-M Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
CTO-AT148002OPEN TO ACCRUAL
A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS)
CTO-BMTCTN1705OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
CTO-BRE18-334OPEN TO ACCRUAL
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
CTO-BTCRC-BRE18-337OPEN TO ACCRUAL
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
CTO-BTCRC-GI15-067OPEN TO ACCRUAL
A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma
CTO-BTCRC-GI20-457OPEN TO ACCRUAL
A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial)
CTO-BTCRC-LUN18-153OPEN TO ACCRUAL
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
CTO-BTCRC-LUN19-396OPEN TO ACCRUAL
A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm), IIA, IIB, and select IIIA [T3N1-2, T4N0-2] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA)
CTO-CAEL101-301OPEN TO ACCRUAL
CTO-CAEL101-302OPEN TO ACCRUAL
CTO-CLR-15-03OPEN TO ACCRUAL
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
CTO-CTMX-2009-002OPEN TO ACCRUAL
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)
CTO-EA1181OPEN TO ACCRUAL
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CTO-EA2186OPEN TO ACCRUAL
CTO-EAZ171OPEN TO ACCRUAL
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
CTO-FGCL-3019-087OPEN TO ACCRUAL
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
CTO-GOG-3053OPEN TO ACCRUAL
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
CTO-IUSCC-0701OPEN TO ACCRUAL
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment with Checkpoint Inhibitor Monotherapy
CTO-IUSCC-0715OPEN TO ACCRUAL
Pilot study of a mobile health strategy to improve medication adherence in breast cancer survivors receiving aromatase inhibitors
CTO-IUSCC-0718OPEN TO ACCRUAL
A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention program
CTO-IUSCC-0722OPEN TO ACCRUAL
Circulating tumor DNA as a predictive biomarker to individualize therapy in patients with stage III non-small cell lung cancer
CTO-IUSCC-0723OPEN TO ACCRUAL
Evaluating the incidence and outcomes of patients with stage III non-small cell lung cancer (NSCLC) whose tumors harbor STK11 and/or Keap1 mutations treated with chemoradiation (CRT) followed by consolidation immunotherapy
CTO-IUSCC-0726OPEN TO ACCRUAL
Significance of STK11/LKB1 or Keap1 mutations in Stage III Non-Small Cell Lung Cancer
CTO-IUSCC-0729OPEN TO ACCRUAL
Non-coding mutations in Multiple Myeloma
CTO-IUSCC-0730OPEN TO ACCRUAL
A Basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1
CTO-IUSCCC-0742OPEN TO ACCRUAL
Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor
CTO-IUSCCC-0752OPEN TO ACCRUAL
A phase II trial evaluating the efficacy of Cabozantinib in the treatment of incurable patients with refractory germ cell tumors
CTO-IUSCCC-0759OPEN TO ACCRUAL
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
CTO-JAB-3312-1003OPEN TO ACCRUAL
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination with Pembrolizumab or Binimetinib in Adult Patients with Advanced Solid Tumors
CTO-LOXO-IDH-20002OPEN TO ACCRUAL
A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations
CTO-LUN18-335OPEN TO ACCRUAL
CTO-M19-345OPEN TO ACCRUAL
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
CTO-MK-3475-866OPEN TO ACCRUAL
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
CTO-MK-3475-905OPEN TO ACCRUAL
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
CTO-MK-3475-937OPEN TO ACCRUAL
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
CTO-NCICOVIDOPEN TO ACCRUAL
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
CTO-PRE0405OPEN TO ACCRUAL
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
CTO-R5458-ONC-1826OPEN TO ACCRUAL
A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
CTO-S1823OPEN TO ACCRUAL
A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS miRNA 371 FOR OUTCOME PREDICTION IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORS
CTO-SNDX-6352-0504OPEN TO ACCRUAL
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
CTO-TAK-981-1503OPEN TO ACCRUAL
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
CTO-UF-STO-PANC-004OPEN TO ACCRUAL
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
DERM-IIR-DFSPOPEN TO ACCRUAL
Dermatofibrosarcoma Protrubrans (DFSP) treated with Mohs Micrographic Surgery: Risk Factors and Treatment Outcomes.
EA4151/BMTCTN1601OPEN TO ACCRUAL
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
ECRO-CELGENE-BB2121-EAP-001OPEN TO ACCRUAL
Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
GI-CPDPC-MATHER-DETECTOPEN TO ACCRUAL
CPDPC 16-04: Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT)
GI-CREATICS-CRTX1-201OPEN TO ACCRUAL
Prospective Collection of Colon Lavage Fluids for Pancreatic Cancer Marker Validation
INCB39110-309OPEN TO ACCRUAL
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
IUCRO-0031OPEN TO ACCRUAL
Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0209OPEN TO ACCRUAL
The Susan G. Komen Tissue Bank at the IU Simon Cancer Center: A Collection and Storage of Biological Specimens Intended for use in the Elucidation of Breast Carcinogenesis
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUCRO-0309OPEN TO ACCRUAL
IU Pancreatic Lesion Tissue/Fluid Bank
IUCRO-0370OPEN TO ACCRUAL
Pathobiology of Paget's Disease
IUCRO-0476OPEN TO ACCRUAL
A Study of the Effect of Sirolimus Levels on Incidence of Hepatic Sinusoidal Obstructive Syndrome
IUCRO-0495OPEN TO ACCRUAL
Creation of a Pancreatic Cancer Outcome Database with Blood Storage
IUSCC-0523OPEN TO ACCRUAL
Perioperative pelvic floor muscle training may improve recovery of continence in men with localized prostate cancer undergoing robot-assisted radical prostatectomy.
IUSCC-0567OPEN TO ACCRUAL
Circulating Tumor Cells (CTC) in Lung Cancer
IUSCC-0579OPEN TO ACCRUAL
Salvage High Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors: Indiana University Experience 1990-2015
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0601OPEN TO ACCRUAL
Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
IUSCC-0605OPEN TO ACCRUAL
Evaluating dose de-escalation in whole brain radiation therapy with simultaneous integrated boost for patients with brain metastases
IUSCC-0608OPEN TO ACCRUAL
T-Cell Leukemia/Lymphoma Biorepository
IUSCC-0611OPEN TO ACCRUAL
Retrospective Analysis of Patients with Metastatic Germ Cell Tumor at Indiana University
IUSCC-0627OPEN TO ACCRUAL
A Phase II Study Analyzing Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients with 1 4 Brain Metastases
IUSCC-0628OPEN TO ACCRUAL
Long-Term Adverse Health Outcomes in Survivors of Germ Cell Tumors Treated with High Dose Chemotherapy
IUSCC-0630OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY AND REGISTRY FOR INFLAMMATORY BREAST CANCER
IUSCC-0633OPEN TO ACCRUAL
Prospective Observation of the Incidence and Natural History of Monoclonal Gammopathy in Patients Undergoing Weight Reduction Surgery
IUSCC-0639OPEN TO ACCRUAL
Comparative analysis of biodynamic imaging utility in predicting response to gemcitabine chemotherapy for human and canine mycosis fungoides
IUSCC-0645OPEN TO ACCRUAL
Description of Cardiotoxicity Associated with Sunitinib in Renal Cell Carcinoma
IUSCC-0649OPEN TO ACCRUAL
Functional and Neurochemical Substrates of Chemotherapy-Related Cognitive Deficits
IUSCC-0658OPEN TO ACCRUAL
The Role of 68Ga-PSMA-11 PET in MRI Fusion Biopsy and Surgery Guidance in Prostate Cancer
IUSCC-0659OPEN TO ACCRUAL
Assessing tobacco use and cessation support among patients with non-tobacco related cancers
IUSCC-0661OPEN TO ACCRUAL
The Indiana Myeloma Registry
IUSCC-0662OPEN TO ACCRUAL
A pilot study evaluating the feasibility and safety of a fasting-mimicking diet in patients receiving systemic treatment for metastatic non-small cell lung cancer
IUSCC-0669OPEN TO ACCRUAL
Evaluating Different Methods of Circulating Tumor DNA Quantification in Oncology Patients
IUSCC-0670OPEN TO ACCRUAL
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting as a Potential Teachable Moment for Actively Smoking Family Members
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0688OPEN TO ACCRUAL
A Retrospective Tissue Analysis of NQO1 Status in Patients with Germ Cell Tumors
IUSCC-0690OPEN TO ACCRUAL
Assessing Exercise Behavior and Preferences Among Patients and Oncologists at Indiana University Simon Cancer Center
IUSCC-0696OPEN TO ACCRUAL
One-on-one exercise program in adolescent and young adult cancer survivors with a certified clinical cancer exercise specialist
IUSCC-0705OPEN TO ACCRUAL
Informational Meetings for Planning And Coordinating Treatment (IMPACT)
IUSCC-0708OPEN TO ACCRUAL
Genomic Analysis of Relapsed/Refractory Germ-Cell Tumors
IUSCC-0709OPEN TO ACCRUAL
Evaluation of MRM-Profiling as a Small Molecule Biomarker-Enrichment Strategy in Oncological Clinical Trials
J11155OPEN TO ACCRUAL
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
NEUR-AGIOS-AG881-C-004OPEN TO ACCRUAL
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
NEUR-ECOG-ACRIN-EAF151OPEN TO ACCRUAL
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NEUR-NCI-NRG-BN007OPEN TO ACCRUAL
A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA.
NEUR-SPRINGWORKS-MEK-NF-201OPEN TO ACCRUAL
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
NSRG-IIR-COHEN-DESIOPEN TO ACCRUAL
Evaluation of intraoperative desorption electrospray ionization mass spectrometry for detection of biomolecules indicative of cancerous versus noncancerous disease state in brain tumors using pathology biopsies.
NURS-IIR-IUSCC-0748OPEN TO ACCRUAL
Biobehavioral correlates of cancer-related cognitive dysfunction and its co-occurring symptoms
NURS-IUSCC-0720OPEN TO ACCRUAL
Biologic Mechanisms and Dosing of Active Music Engagement in Children with Acute Lymphoblastic Leukemia and Parents
OTHN-IIR-IUSCC-0685OPEN TO ACCRUAL
Characterization of Cachexia in Tissues from Head and Neck Surgery Patients Receiving Free Flap Reconstruction.
OTHN-IIR-IUSCC-0733OPEN TO ACCRUAL
Functional and Molecular Analysis of Muscle in Patients With and Without Head and Neck Cancer Cachexia
PHARM-IIR-IUSCC-0735OPEN TO ACCRUAL
A Human Factors Engineering Approach to Understand Safety Vulnerabilities in Ambulatory Administration of 5-Fluorouracil (5-FU)
PHO-BAYER-ADVL1721OPEN TO ACCRUAL
A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
PHO-COG-AALL1731OPEN TO ACCRUAL
Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma.
PHO-COG-AALL1732OPEN TO ACCRUAL
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
PHO-COG-AAML1831OPEN TO ACCRUAL
AAML1831, A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
PHO-COG-AAML18P1OPEN TO ACCRUAL
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
PHO-COG-ACNS1721OPEN TO ACCRUAL
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
PHO-COG-ACNS1831OPEN TO ACCRUAL
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG).
PHO-COG-ACNS1833OPEN TO ACCRUAL
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
PHO-COG-ACNS1931OPEN TO ACCRUAL
A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
PHO-COG-ADVL1823OPEN TO ACCRUAL
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia.
PHO-COG-ADVL18P1OPEN TO ACCRUAL
ADVL18P1, AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION.
PHO-COG-AGCT1532OPEN TO ACCRUAL
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
PHO-COG-AHEP1531OPEN TO ACCRUAL
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
PHO-COG-ALTE2031OPEN TO ACCRUAL
1169 - ALTE2031, StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors.
PHO-COG-ANBL1531OPEN TO ACCRUAL
A Phase 3 Study of 131-I-Metaiodobenzylguanidine (131-I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
PHO-COG-ANBL1821OPEN TO ACCRUAL
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
PHO-COG-ANBL19P1OPEN TO ACCRUAL
ANBL19P1; A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
PHO-COG-AREN1721OPEN TO ACCRUAL
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
PHO-COG-AREN1921OPEN TO ACCRUAL
AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
PHO-COG-CROOP-ADVL1414OPEN TO ACCRUAL
A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
PHO-COG-CROOP-ADVL1822OPEN TO ACCRUAL
A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT MAINTENANCE THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
PHO-COG-FALLON-AAML1531OPEN TO ACCRUAL
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
PHO-COG-FALLON-AGCT1531OPEN TO ACCRUAL
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-ANBL1232OPEN TO ACCRUAL
ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
PHO-COG-FALLON-APEC14B1OPEN TO ACCRUAL
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PHO-COG-NCICOVIDOPEN TO ACCRUAL
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study.
PHO-COG-PEPN1812OPEN TO ACCRUAL
A PHASE 1 TRIAL OF THE CD123 X CD3 DUAL AFFINITY RE-TARGETING ANTIBODY FLOTETUZUMAB (NSC#808294, IND#145986) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
PHO-CROOP-AMGEN-20110261OPEN TO ACCRUAL
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous System Tumors That are Amenable to Direct Injection Advanced Non Central Nervous SystemTumors That are Amenable to Direct Injection
PHO-DOD-NF110OPEN TO ACCRUAL
NF110: Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
PHO-EISAI-E7080-G000-230OPEN TO ACCRUAL
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)
PHO-FALLON-COG-AALL1621OPEN TO ACCRUAL
AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
PHO-FALLON-COG-ARST1431OPEN TO ACCRUAL
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
PHO-FALON-INCYTE-AALL1521OPEN TO ACCRUAL
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
PHO-IIR-COVID-19-DISTRESSOPEN TO ACCRUAL
Distress during COVID-19 Pandemic for Caregivers of Children with Hematologic and Oncologic Diagnoses.
PHO-IIR-INFECTIOUSDISEASEOPEN TO ACCRUAL
Infectious Disease Outcomes in Pediatric Oncology Patients.
PHO-IIR-IUSCC-0728OPEN TO ACCRUAL
Assessing the utility of ammonia levels as a tool for veno-occlusive disease (VOD) diagnosis.
PHO-JANSSEN-AALL2005OPEN TO ACCRUAL
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects 1 and 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
PHO-LILLY-JV01-ADVL2021AOPEN TO ACCRUAL
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients andYoung Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
PHO-LILLY-JV02-ADVL2021BOPEN TO ACCRUAL
Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma
PHO-MERCK-KEYNOTE-667OPEN TO ACCRUAL
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
PHO-NCI-SURVIVORLINKOPEN TO ACCRUAL
SurvivorLink: Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers
PHO-NOVARTIS-CCTL019G2201JOPEN TO ACCRUAL
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
PHO-NOVARTISMAPS-SKILESOPEN TO ACCRUAL
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
PHO-PBMTC-ENDRADOPEN TO ACCRUAL
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
PHO-PFIZER-AAML1921OPEN TO ACCRUAL
Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic or resistant/intolerant Ph+ Chronic Myeloid Leukemia.
PHO-PFIZER-PRADHAN-ADVL1921OPEN TO ACCRUAL
PHO-PRADHAN-COG-AALL1631OPEN TO ACCRUAL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
PHO-PRADHAN-COG-ACNS1422-OPEN TO ACCRUAL
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
PHO-PRADHAN-COG-ADVL1521OPEN TO ACCRUAL
A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
PHO-PRADHAN-COG-ALTE1631OPEN TO ACCRUAL
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
PHO-PRADHAN-COG-ALTE16C1OPEN TO ACCRUAL
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
PHO-PRADHAN-COG-APEC1621OPEN TO ACCRUAL
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)MASTER VERSION CONTROL PROTOCOL
PHO-PRADHAN-MERK-ADVL1621OPEN TO ACCRUAL
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
PHO-SEATTLE-PLAT-05OPEN TO ACCRUAL
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T Cell Immunotherapy for CD19+CD22+ Leukemia.
PHO-SHIH-NWC-HEADSTART4OPEN TO ACCRUAL
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE
PHO-STJUDE-AML16OPEN TO ACCRUAL
A PHASE II TRIAL OF EPIGENETIC PRIMING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
PSY-IIR-IUSCC-0698OPEN TO ACCRUAL
Telephone Support for Metastatic Breast Cancer Patients
PULM-IIR-DRCOPEN TO ACCRUAL
Analysis of DRC in lung disease
RADY-ECOG-WESTPHAL-EA1151OPEN TO ACCRUAL
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA1151
RADY-FIVEELEVEN-GREEN-GAOPEN TO ACCRUAL
Biodistribution and dosimetry of the investigational PET agent 68Ga-P16-093 in prostate cancer patients
RADY-GU-SAYKIN-TLCOPEN TO ACCRUAL
Older Breast Cancer Patients: Risk for Cognitive Decline
RADY-IIR-CBTOPEN TO ACCRUAL
Mobile Device CBT for Chemotherapy-Related Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial
RADY-IUSCC-0725OPEN TO ACCRUAL
Yttrium-90 Radiation Segmentectomy versus Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Early Stage Hepatocellular Carcinoma (HCC): A Pilot Study
RAON-IIR-IUSCC-0710OPEN TO ACCRUAL
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
RAON-IIR-IUSCC-0711OPEN TO ACCRUAL
Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients with Lung Tumors in Close Proximity to the Chest Wall
RAON-IIR-IUSCC-0745OPEN TO ACCRUAL
A Prospective Pilot Trial Evaluating a 3D Printed Oral Stent Device with Suction for Oral Cancer Radiation Treatment
RAON-STANFORD-AVATAROPEN TO ACCRUAL
AVATAR anesthesia alternative in pediatric radiotherapy: A Multi-Center Pilot Study
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
SNEU-GTMEDICAL-STARTOPEN TO ACCRUAL
A Multicenter Observational Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms
SNEU-IIR-RIMTIHOPEN TO ACCRUAL
Role of Inflammatory Mediators in Tumor-Induced Hydrocephalus
STU00077147OPEN TO ACCRUAL
Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer
SURG-BOSTONSC-E7107OPEN TO ACCRUAL
Intra-operative Pancreatoscopy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN)
SURG-DAVOL-PREVENTOPEN TO ACCRUAL
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy
SURG-IIR-COVID-19-RESPONSEOPEN TO ACCRUAL
Impact of the Initial COVID-19 Response and the Following Delayed Care Surge on Patients Requiring Emergent, Urgent, and Elective Surgical Procedures
SURG-IIR-CTDNAOPEN TO ACCRUAL
A phase I feasibility study to identify circulating tumor DNA in patients with Barrett's epithelium and early stage esophageal adenocarcinoma treated with endoscopic mucosal resection
SURG-TAKEDA-954-2004OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-Bowel Resection
TBCRC034OPEN TO ACCRUAL
The incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in patients diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy
TBCRC042OPEN TO ACCRUAL
A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
U54-IUSCCC-0761OPEN TO ACCRUAL
Preventing cervical cancer in HIV-infected Kenyan and Ugandan women
UROL-CC-IUSCCC-0760OPEN TO ACCRUAL
The Role of 68Ga-PSMA-11 PET in Surgery Guidance in Prostate Cancer: A prospective Pilot trial